AI Carb Counter for Type 1 Diabetes Now Available on Android Devices

Innovative Tool for Type 1 Diabetes Management

In a significant leap forward for Type 1 diabetes management, Curecode Co., Ltd., in collaboration with Toyama University, has announced the launch of the AI Carb Counter system, now compatible with Android devices. The AI Carb Counter aims to provide accurate insulin dosing recommendations by analyzing patients' pre-meal blood glucose levels and carbohydrate intake.

Background on Type 1 Diabetes

Type 1 diabetes is a chronic autoimmune condition where the body's immune system attacks insulin-producing beta cells in the pancreas. This leads to a lifelong dependency on insulin injections. In Japan alone, it is estimated that between 100,000 to 140,000 individuals are living with Type 1 diabetes. Traditionally, these patients have faced challenges in managing their blood sugar levels effectively, often needing to maintain a consistent diet due to the complexities involved in insulin dosing. Changing dietary habits typically required consultations with healthcare providers, which was not always practical and could significantly lower the patients' quality of life.

Aligning with Android Devices

The AI Carb Counter serves as a research tool for Type 1 diabetes patients to assess their daily insulin needs. By utilizing photographs of meals, the AI can estimate the carbohydrate content, which is then used to calculate the recommended insulin dosage. Currently, the system is undergoing clinical trials to validate its efficacy and safety. The new Android compatibility enables more patients to participate in this important research, alongside those already using iOS devices.

Specialized Diabetes Clinic at International University of Health and Welfare

In a further development, the International University of Health and Welfare Ichikawa Hospital has launched a specialized outpatient clinic dedicated to advanced care for Type 1 diabetes. Led by Professor Daisuke Nakajo, who also spearheads the AI Carb Counter project, this clinic aims to provide cutting-edge treatments and develop protocols for diabetes management. The hospital has implemented state-of-the-art medical equipment and established a comprehensive system for clinical research since its inception.

For more details about the specialized clinic, visit here.

Future Development Plans

The AI Carb Counter utilizes a calculation formula to determine suitable insulin doses based on a variety of input metrics, including pre-meal glucose levels and carbohydrate intake. These parameters are pre-set by healthcare professionals, taking patients' lifestyle patterns and health statuses into account. However, daily fluctuations in these values can make it challenging to maintain correct insulin levels, potentially leading to dangerous situations like hypoglycemia or hyperglycemia.

Recognizing the unpredictable nature of blood sugar levels, the research team aims to develop more advanced AI capabilities. Building on the data gathered from the initial clinical trials—including blood sugar levels, insulin administration logs, and daily health reports—the goal is for the AI to predict carbohydrate counts more accurately, thereby optimizing the insulin delivery according to each patient's unique needs.

Research Collaboration

As a result of Professor Nakajo’s transition to the new project team, the partnership structure has been modified to include:

- Curecode Co., Ltd.
- International University of Health and Welfare
- Toyama University

Guided by this new framework, the project continues to focus on creating innovative applications that support the lives of Type 1 diabetes patients. Clinical trials will compare outcomes between users of the app and those without it, gathering critical data on its effectiveness. Recruitment is ongoing for participants willing to engage in these clinical tests.

For more information and participation details, visit here.

The overarching mission is to empower diabetes patients to lead secure and fulfilling lives with improved health management tools. Future advancements will focus on integrating user feedback and technological innovations to enhance the app's functionality and effectiveness.

About Curecode Co., Ltd.

Founded in 2011, Curecode is an IT venture committed to health tech innovation across healthcare, nursing, and well-being sectors. The company is involved not only in developing healthcare applications but also in design, operation management, and customer support. Strengthening partnerships with local governments and academic institutions is a key aspect of their strategy.

Corporate Details

- Company Name: Curecode Co., Ltd.
- Headquarters: Toyama Prefecture, Japan (moved on February 3, 2023)
- Executive: CEO Fumitaka Tsuchida
- Website: curecode.jp

Employment Opportunities

Join Curecode's mission to enhance health and well-being through IT! The health tech field offers immense opportunities, and the company is currently seeking IT engineers for system and application development, as well as corporate sales roles.
For more information on career opportunities, visit here.

For press inquiries, contact: Sasaki, Curecode Co., Ltd.